Entera Bio Ltd. (NASDAQ: ENTX)
$1.87
N/A ( 0% ) 98.0K
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Market Data
Open
$1.87
Previous close
$1.87
Volume
98.0K
Market cap
$69.55M
Day range
$1.84 - $1.98
52 week range
$0.52 - $3.35
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jan 03, 2024 |
4 | Insider transactions | 1 | Jan 03, 2024 |
4 | Insider transactions | 1 | Dec 27, 2023 |
4 | Insider transactions | 1 | Dec 27, 2023 |
8-k | 8K-related | 18 | Dec 26, 2023 |
10-q | Quarterly Reports | 40 | Nov 14, 2023 |
8-k | 8K-related | 15 | Nov 14, 2023 |
4 | Insider transactions | 1 | Sep 14, 2023 |
4 | Insider transactions | 1 | Sep 14, 2023 |
8-k | 8K-related | 12 | Sep 13, 2023 |